Poor prognosis of HIV-associated tuberculous meningitis regardless of the timing of antiretroviral therapy

Clinical Infectious Diseases

Volumn 52, Issue 11, 2011, Pages 1384-1387

  Lawn, Stephen D ^a,b   Wood, Robin ^a  

^a UNIVERSITY OF CAPE TOWN   (South Africa)

^b LONDON SCHOOL OF HYGIENE AND TROPICAL MEDICINE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT; COTRIMOXAZOLE; ISONIAZID; PLACEBO; TUBERCULOSTATIC AGENT;

COMORBIDITY; DISEASE ASSOCIATION; DISEASE SEVERITY; DRUG SENSITIVITY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MORTALITY; PRIORITY JOURNAL; PROGNOSIS; REVIEW; RISK FACTOR; TREATMENT PLANNING; TUBERCULOUS MENINGITIS;

ANTI-HIV AGENTS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; ANTITUBERCULAR AGENTS; HIV INFECTIONS; HUMANS; PROGNOSIS; TREATMENT OUTCOME; TUBERCULOSIS, MENINGEAL;

EID: 79957452047     PISSN: 10584838     EISSN: 15376591     Source Type: Journal    
DOI: 10.1093/cid/cir239     Document Type: Review

References (27)

1. Lawn SD, Churchyard G. Epidemiology of HIV-associated tuberculosis. Curr Opin HIV AIDS 2009; 4:325-333.
2. Harries AD, Zachariah R, Corbett EL, et al. The HIV-associated tuberculosis epidemic-when will we act? Lancet 2010; 375:1906-1919.
3. Lawn SD, Kranzer K, Wood R. Antiretroviral therapy for control of the HIV-associated tuberculosis epidemic in resource-limited settings. Clin Chest Med 2009; 30:685-699.
4. Harries AD, Zachariah R, Lawn SD. Providing HIV care for co-infected tuberculosis patients: A perspective from sub-Saharan Africa. Int J Tuberc Lung Dis 2009; 13:6-16.
5. Kaplan JE, Benson C, Holmes KH, Brooks JT, Pau A, Masur H. Guidelines for prevention and treatment of opportunistic infections in HIV-infected adults and adolescents: Recommendations from CDC, the National Institutes of Health, and the HIV Medicine Association of the Infectious Diseases Society of America. MMWR Recomm Rep 2009; 58:1-207.
6. Lawn SD, Torok ME, Wood R. Optimum time to start antiretroviral therapy during HIV-associated opportunistic infections. Curr Opin Infect Dis 2011; 24:34-42.
7. Lawn SD, Wood R. Optimum time to initiate antiretroviral therapy in patients with HIV-associated tuberculosis: There may be more than one right answer. J Acquir Immune Defic Syndr 2007; 46:121-123. (Pubitemid 47507443)
8. Manosuthi W, Chottanapand S, Thongyen S, Chaovavanich A, Sungkanuparph S. Survival rate and risk factors of mortality among HIV/tuberculosis-coinfected patients with and without antiretroviral therapy. J Acquir Immune Defic Syndr 2006; 43:42-46. (Pubitemid 44306486)
9. Velasco M, Castilla V, Sanz J, et al. Effect of simultaneous use of highly active antiretroviral therapy on survival of HIV patients with tuberculosis. J Acquir Immune Defic Syndr 2009; 50:148-152.
10. Blanc F-X, Sok T, Laureillard D, et al. Significant enhancement in survival with early (2 weeks) vs late (8 weeks) initiation of highly active antiretroviral treatment (HAART) in severely immunosuppressed HIV-infected adults with newly diagnosed tuberculosis (abstract THLBB1). In: Program and abstracts of the XVIII International AIDS Conference, Vienna, Austria: International AIDS Society, 2010.
11. Abdool Karim SS, Naidoo K, Grobler A, et al. Timing of initiation of antiretroviral drugs during tuberculosis therapy. N Engl J Med 2010; 362:697-706.
12. World Health Organization. Antiretroviral therapy for HIV infection in adults and adolescents. Recommendations for a publc health approach (2010 revision). Geneva, Switzerland: World Health Organization. http://www.who.int/ hiv/pub/arv/adult/en/index.html. Accessed 19 December 2010.
13. Török ME, Yen NTB, Chau TTH, et al. Timing of initiation of antiretroviral therapy in human immunodeficiency virusassociated tuberculous meningitis. Clin Infect Dis 2011; 52:1376-85.
14. Badri M, Lawn SD, Wood R. Short-term risk of AIDS or death in people infected with HIV-1 before antiretroviral therapy in South Africa: A longitudinal study. Lancet 2006; 368:1254-1259. (Pubitemid 44508698)
15. Lawn SD, Harries AD, Anglaret X, Myer L, Wood R. Early mortality among adults accessing antiretroviral treatment programmes in sub-Saharan Africa. AIDS 2008; 22:1897-1908.
16. Lawn SD, Little F, Bekker LG, et al. Changing mortality risk associated with CD4 cell response to antiretroviral therapy in South Africa. AIDS 2009; 23:335-342.
17. Torok ME, Chau TT, Mai PP, et al. Clinical and microbiological features of HIV-associated tuberculous meningitis in Vietnamese adults. PLoS One 2008; 3:e1772.
18. Thwaites GE, Nguyen DB, Nguyen HD, et al. Dexamethasone for the treatment of tuberculous meningitis in adolescents and adults. N Engl J Med 2004; 351: 1741-1751.
19. Thwaites GE, Lan NT, Dung NH, et al. Effect of antituberculosis drug resistance on response to treatment and outcome in adults with tuberculous meningitis. J Infect Dis 2005; 192:79-88. (Pubitemid 40863860)
20. Vinnard C, Winston CA, Wileyto EP, MacGregor RR, Bisson GP. Isoniazid resistance and death in patients with tuberculous meningitis: Retrospective cohort study. BMJ 2010; 341:c4451.
21. Lawn SD, Bekker LG, Miller RF. Immune reconstitution disease associated with mycobacterial infections in HIV-infected individuals receiving antiretrovirals. Lancet Infect Dis 2005; 5:361-373. (Pubitemid 40779257)
22. Torok ME, Kambugu A, Wright E. Immune reconstitution disease of the central nervous system. Curr Opin HIV AIDS 2008; 3: 438-445.
23. Boehme CC, Nabeta P, Hillemann D, et al. Rapid molecular detection of tuberculosis and rifampin resistance. N Engl J Med 2010; 363:1005-1015.
24. Lawn SD, Harries AD, Wood R. Strategies to reduce early morbidity and mortality in adults receiving antiretroviral therapy in resource-limited settings. Curr Opin HIV AIDS 2010; 5:18-26.
25. Lawn SD, Wood R, De Cock KM, Kranzer K, Lewis JJ, Churchyard GJ. Antiretrovirals and isoniazid preventive therapy in the prevention of HIV-associated tuberculosis in settings with limited health-care resources. Lancet Infect Dis 2010; 10:489-498.
26. Zolopa A, Andersen J, Powderly W, et al. Early antiretroviral therapy reduces AIDS progression/death in individuals with acute opportunistic infections: A multicenter randomized strategy trial. PLoS One 2009; 4:e5575.
27. Makadzange AT, Ndhlovu CE, Takarinda K, et al. Early versus delayed initiation of antiretroviral therapy for concurrent HIV infection and cryptococcal meningitis in subsaharan Africa. Clin Infect Dis 2010; 50:1532-1538.